Estrogen and Progesterone Explained

Educational only. Not medical advice. The choice of hormone type and combination is a clinical decision based on your individual health history, uterine status, and risk factors. Discuss specific options with your clinician.

The WHI study that terrified a generation of women and their doctors tested one specific combination: conjugated equine estrogens plus medroxyprogesterone acetate. Applying those results to all HRT regimens is like testing one brand of car and concluding that all cars are unsafe. The type of estrogen matters. The type of progestogen matters more. Understanding the difference between what the WHI studied and what your clinician is actually prescribing is one of the most consequential things you can do before starting treatment.

• Estradiol (the primary human estrogen) is available as an FDA-approved bioidentical product - you do not need compounded estrogen to get bioidentical estrogen
• Conjugated equine estrogens (Premarin) are a different product from estradiol - they contain multiple estrogen compounds derived from horse urine and are what the WHI studied
• Micronized progesterone (Prometrium) may carry lower breast cancer risk than synthetic MPA (Provera) based on the E3N cohort study (RR 1.00 vs RR 1.40)
• The progestogen type matters clinically - applying the WHI’s breast cancer findings (which used MPA) to micronized progesterone overstates the evidence
• If you have a uterus, you need a progestogen with estrogen. No exceptions

Estradiol (17-beta estradiol). The primary estrogen your ovaries produced. This is what “bioidentical estrogen” actually means. Available as FDA-approved oral tablets (Estrace, generics for $4 to 15 per month), transdermal patches (Climara, Vivelle-Dot, generics), topical gels (EstroGel, Divigel), and vaginal products. You can get bioidentical estrogen at Walmart for $4.

Conjugated equine estrogens (CEE/Premarin). Derived from pregnant mare urine. Contains a mixture of estrogen compounds including estrone sulfate and equilin. This is what the WHI used. It has the longest clinical track record of any estrogen product, but it is a different pharmacological product from estradiol. It is not bioidentical.

This is where the distinction matters most for your risk.

Micronized progesterone (Prometrium, generics). Bioidentical - structurally identical to the progesterone your body made before menopause. FDA-approved. The E3N cohort study (approximately 80,000 women) found that estrogen combined with micronized progesterone showed no statistically significant increase in breast cancer risk after up to 5 years (relative risk approximately 1.00). The same study found estrogen combined with synthetic progestins showed a relative risk of approximately 1.40. This is observational data, not a randomized trial, but the signal is consistent and biologically plausible. Has a natural sedative effect - take at bedtime. Contains peanut oil (relevant for allergies). $15 to 50 per month generic.

Medroxyprogesterone acetate (MPA/Provera). The synthetic progestin the WHI used in the combination that showed increased breast cancer risk. MPA has a different receptor binding profile than micronized progesterone, with more proliferative effect on breast tissue in laboratory studies. Still widely prescribed, but many menopause specialists now preferentially prescribe micronized progesterone based on the accumulating evidence.

Norethindrone acetate. Another synthetic progestin, available in combination patches (CombiPatch) and oral formulations. Commonly used because of patch combination availability. Less data on breast cancer risk compared to both MPA and micronized progesterone.

Levonorgestrel IUD (Mirena). Delivers progestogen directly to the uterus. Growing clinical use for endometrial protection alongside systemic estrogen. Off-label for this indication but routinely used by many menopause specialists. The Mirena lasts up to 8 years for contraception, though its duration specifically for HRT endometrial protection is less established. The advantage: local progestogen delivery with minimal systemic effects, meaning fewer mood, bloating, and breast tenderness side effects than oral progestogens. The evidence gap: long-term data specifically for HRT endometrial protection is more limited than for oral progestogens. “Off-label” does not mean “unsupported” - it means “not yet formally studied for this specific indication.”

The 2019 Lancet Collaborative Group meta-analysis pooled data from 58 studies and found that all types of combined HRT were associated with some increase in breast cancer risk. Critics argue this analysis grouped heterogeneous progestogens together, underweighting the progesterone-type distinction. The individual study data (including E3N) suggest micronized progesterone carries lower risk than MPA specifically.

The clinical takeaway: the evidence suggests, but does not definitively prove, that micronized progesterone is the safer progestogen option. Many menopause specialists prescribe it as their default. If your clinician is prescribing MPA without discussing alternatives, ask why. There should be a clinical reason beyond habit.

The E3N Study In Detail

The French E3N cohort followed approximately 80,000 postmenopausal women. Key findings relevant to progesterone type:

Estrogen combined with micronized progesterone: relative risk of breast cancer approximately 1.00 (no significant increase) after up to 5 years of use. Estrogen combined with synthetic progestins (including MPA, norethindrone, and others): relative risk approximately 1.40 (40% increase) with similar duration.

This is observational data, not a randomized trial. It cannot prove causation. But the biological plausibility is strong - micronized progesterone has a different receptor binding profile than synthetic progestins, with less proliferative effect on breast tissue in laboratory studies.

• Are you prescribing estradiol or conjugated equine estrogens, and what is your rationale?
• Which progestogen are you recommending - micronized progesterone or a synthetic progestin - and why?
• How does the hormone combination you are prescribing relate to the WHI findings?
• If I have a uterus, can I use a levonorgestrel IUD for endometrial protection instead of oral progestogen?